8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

[1]  S. Haneuse,et al.  Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care , 2018, Annals of Internal Medicine.

[2]  Jung-Han Kim,et al.  Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.

[3]  A. Aminian,et al.  ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m2). , 2018, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[4]  J. Hjelmesæth,et al.  Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities , 2018, JAMA.

[5]  B. Wolfe,et al.  Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study , 2017, JAMA surgery.

[6]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[7]  G. Fernández-Ranvier,et al.  Preoperative insulin therapy as a marker for type 2 diabetes remission in obese patients after bariatric surgery. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[8]  Shelby Sullivan Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes , 2017, Diabetes Spectrum.

[9]  K. Fujioka,et al.  Obesity Pharmacotherapy in Patients With Type 2 Diabetes , 2017, Diabetes Spectrum.

[10]  James H. Faghmous,et al.  Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. , 2017, The lancet. Diabetes & endocrinology.

[11]  K. Truong,et al.  The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis , 2017, Obesity Surgery.

[12]  Raymond L. Forbes,et al.  3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial , 2017, The Lancet.

[13]  L. Genser,et al.  Bariatric surgery versus intensive medical therapy for diabetes -5- year outcomes , 2017 .

[14]  P. O’Brien,et al.  Five-Year Outcomes of a Randomized Trial of Gastric Band Surgery in Overweight but Not Obese People With Type 2 Diabetes , 2017, Diabetes Care.

[15]  V. Montori,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2017, JAMA.

[16]  C. Burant,et al.  Impact of weight loss on waist circumference and the components of the metabolic syndrome , 2017, BMJ Open Diabetes Research and Care.

[17]  L. Ji,et al.  Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis , 2016, PloS one.

[18]  W. Herman,et al.  Reconciliation of Type 2 Diabetes Remission Rates in Studies of Roux-en-Y Gastric Bypass , 2016, Diabetes Care.

[19]  P. Schauer,et al.  The Socioeconomic Impact of Morbid Obesity and Factors Affecting Access to Obesity Surgery. , 2016, The Surgical clinics of North America.

[20]  Avis J. Thomas,et al.  Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial , 2016, Diabetes Care.

[21]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.

[22]  F. Rubino,et al.  Identifying Barriers to Appropriate Use of Metabolic/Bariatric Surgery for Type 2 Diabetes Treatment: Policy Lab Results , 2016, Diabetes Care.

[23]  R. Eckel,et al.  Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications , 2016, Diabetes Care.

[24]  B. Wolfe,et al.  Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes , 2016, Diabetes Care.

[25]  P. Schauer,et al.  Bariatric Surgery in Obese Patients With Type 1 Diabetes , 2016, Diabetes Care.

[26]  Benjamin Aribisala,et al.  Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders , 2016, Diabetes Care.

[27]  D. Flum,et al.  Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial , 2016, Diabetologia.

[28]  D. Redelmeier,et al.  Self-harm Emergencies After Bariatric Surgery: A Population-Based Cohort Study. , 2016, JAMA surgery.

[29]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations , 2016, Obesity Surgery.

[30]  M. Talamini,et al.  Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York , 2016, Surgical Endoscopy.

[31]  Chih-Cheng Hsu,et al.  Effect of Bariatric Surgery vs Medical Treatment on Type 2 Diabetes in Patients With Body Mass Index Lower Than 35: Five-Year Outcomes. , 2015, JAMA surgery.

[32]  F. Rubino,et al.  Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.

[33]  J. Boucher,et al.  Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.

[34]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[35]  J. Clark,et al.  Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy , 2015, Obesity.

[36]  N. Nguyen,et al.  Use and Outcomes of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Gastric Bypass: Analysis of the American College of Surgeons NSQIP. , 2015, Journal of the American College of Surgeons.

[37]  E. Mayer-Davis,et al.  Partial meal replacement plan and quality of the diet at one year: Action for Health in Diabetes (Look AHEAD) Trial , 2015 .

[38]  Markku Peltonen,et al.  Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study , 2015, Diabetologia.

[39]  S. Bleich,et al.  Efficacy of commercial weight-loss programs: an updated systematic review. , 2015, Annals of internal medicine.

[40]  S. Kahn,et al.  Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes , 2015, Diabetes Care.

[41]  P. Schauer,et al.  How safe is metabolic/diabetes surgery? , 2015, Diabetes, obesity & metabolism.

[42]  V. Montori,et al.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[43]  E. Livingston,et al.  Association between bariatric surgery and long-term survival. , 2015, JAMA.

[44]  Y. Bao,et al.  Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. , 2015, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[45]  M. Gulliford,et al.  Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. , 2014, The lancet. Diabetes & endocrinology.

[46]  A. Kyriacou,et al.  Time to end medical nihilism in non-surgical weight management , 2014 .

[47]  D. Ryan,et al.  Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release , 2014, Diabetes Care.

[48]  Kristian Thorlund,et al.  Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. , 2014, JAMA.

[49]  A. Goldfine,et al.  Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. , 2014, JAMA surgery.

[50]  W. Herman,et al.  Very-low-energy diet for type 2 diabetes: an underutilized therapy? , 2014, Journal of diabetes and its complications.

[51]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[52]  C. Bouchard,et al.  Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. , 2014, JAMA.

[53]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.

[54]  R. Henry,et al.  Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release , 2014, Diabetes Care.

[55]  John P H Wilding The importance of weight management in type 2 diabetes mellitus , 2014, International journal of clinical practice.

[56]  D. Cummings,et al.  Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. , 2014, The lancet. Diabetes & endocrinology.

[57]  A. Schwartz,et al.  Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study , 2014, Obesity.

[58]  M. Neovius,et al.  Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials123 , 2013, The American journal of clinical nutrition.

[59]  Luis Garcia,et al.  Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.

[60]  F. Greenway,et al.  Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes , 2013, Diabetes Care.

[61]  K. Gadde,et al.  Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults , 2013, Obesity.

[62]  J. Birkmeyer,et al.  Surgical skill and complication rates after bariatric surgery. , 2013, The New England journal of medicine.

[63]  M. Kroh,et al.  Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus , 2013, Annals of surgery.

[64]  M. Bessler,et al.  Very Low–Calorie Diet Mimics the Early Beneficial Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity and β-Cell Function in Type 2 Diabetic Patients , 2013, Diabetes.

[65]  X. Ouyang,et al.  Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. , 2013, Diabetes research and clinical practice.

[66]  A. Kersting,et al.  Risk of completed suicide after bariatric surgery: a systematic review , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[67]  Daniel B. Jones,et al.  Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society for metabolic & bariatric surgery* , 2013, Obesity.

[68]  A. Geliebter,et al.  Substance use following bariatric weight loss surgery. , 2013, JAMA surgery.

[69]  S. Hunt,et al.  Health benefits of gastric bypass surgery after 6 years. , 2012, JAMA.

[70]  P. O'Neil,et al.  Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.

[71]  D. Cummings,et al.  Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity , 2012, Diabetes Care.

[72]  G. Bray,et al.  Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. , 2012, The American journal of clinical nutrition.

[73]  G. Wakabayashi,et al.  IFSO-APC Consensus Statements 2011 , 2012, Obesity Surgery.

[74]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[75]  S. Haneuse,et al.  A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass , 2012, Obesity Surgery.

[76]  Daniel B. Jones,et al.  First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.

[77]  F. Rubino,et al.  IDF's view of bariatric surgery in type 2 diabetes , 2011, The Lancet.

[78]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[79]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[80]  Ross Ward,et al.  American Association of Clinical Endocrinologists , 2011 .

[81]  J. Birkmeyer,et al.  Hospital complication rates with bariatric surgery in Michigan. , 2010, JAMA.

[82]  F. Rubino,et al.  The Diabetes Surgery Summit Consensus Conference: Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus , 2010, Annals of surgery.

[83]  Donald A Williamson,et al.  Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. , 2009, The New England journal of medicine.

[84]  N. Nguyen,et al.  A Prospective Randomized Trial of Laparoscopic Gastric Bypass Versus Laparoscopic Adjustable Gastric Banding for the Treatment of Morbid Obesity: Outcomes, Quality of Life, and Costs , 2009, Annals of surgery.

[85]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[86]  B. Wolfe,et al.  Perioperative safety in the longitudinal assessment of bariatric surgery. , 2009, The New England journal of medicine.

[87]  C. Bouchard,et al.  Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. , 2009, The Lancet. Oncology.

[88]  I. Greenberg,et al.  Behavioral and Psychological Care in Weight Loss Surgery: Best Practice Update , 2009, Obesity.

[89]  C. Apovian,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, THE OBESITY SOCIETY, AND AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE PERIOPERATIVE NUTRITIONAL, METABOLIC, AND NONSURGICAL SUPPORT OF THE BARIATRIC SURGERY PATIENT , 2009, Obesity.

[90]  Bryan K. Smith,et al.  American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. , 2009, Medicine and science in sports and exercise.

[91]  D. Dempsey,et al.  Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects , 2008 .

[92]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[93]  T. Wadden,et al.  The Evolution of Very‐Low‐Calorie Diets: An Update and Meta‐analysis , 2006, Obesity.

[94]  A. Kaiser Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. , 2005, The New England journal of medicine.

[95]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[96]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[97]  2 nd International DAWN Summit : a call-to-action to improve psychosocial care for people with diabetes , 2004 .

[98]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[99]  M. Franz,et al.  The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.

[100]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[101]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[102]  B. Goldstein,et al.  Beneficial health effects of modest weight loss. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[103]  UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. , 1990, Metabolism: clinical and experimental.